Eganelisib, also known as IPI-549, is an experimental compound that functions as a highly selective inhibitor of phosphoinositide 3-kinase gamma (PI3Kγ). It is under investigation in research settings for its potential role in disrupting the PI3K/AKT/mTOR signaling pathway, which is implicated in cancer development.
Alcance del contenido: La información de esta página se refiere a la identificación química y a los contextos de suministro industrial, investigación y producción. No constituye una afirmación terapéutica, un consejo médico ni instrucciones de uso de medicamentos.
¿Adquiriendo o suministrando este compuesto?
Publique su inventario o una solicitud de compra
CAS 1693758-51-8
4-Tolylsulfonylurea
Major metabolite of tolbutamide
Glucagonum
active pharmaceutical ingredient
Deracoxib
selective cyclooxygenase 2 inhibitor
Celecoxib
cyclooxygenase 2 inhibitor
2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide
XUMALORDVCFWKV-IBGZPJMESA-N
C[C@@H](C1=CC2=C(C(=CC=C2)C#CC3=CN(N=C3)C)C(=O)N1C4=CC=CC=C4)NC(=O)C5=C6N=CC=CN6N=C5N